Disparities in clinical trials must become a thing of the past. Inclusion of race, sex, age, genetics, demographics and geographies in clinical trial designs allows us to achieve relevant healthcare solutions that meet the needs of diverse patient populations. Read more here: https://lnkd.in/erYSU5db #ClinicalTrials #Diversity
Certainly a very commendable effort and a goal the entire industry should support. It is just important to do this in a compliant manner and to respect data privacy and other regulations around the world. First and foremost a defensible narrative is required, not to collect diversity data solely for the sake of collecting diversity data. Authorities like the FDA articulate clear requirements in that respect, but such requirements may not justify the collection of diversity in other parts of the world, e.g. in GDPR countries. Processing diversity data is only sustainable when it is done in a compliant manner.
Totally agree Boehringer Ingelheim! Technology is key to making studies more efficient and reducing site burden. Our Clinical Trial Risk Tool uses AI and NLP to improve protocol assessments. Check it out: https://clinicaltrialrisk.org/
100%! This is why I love working at Boehringer Ingelheim. Thanks for this important message Lykke. Your leadership is inspiring 💗.
Absolutely 💯 Boehringer Ingelheim Lykke Hinsch Gylvin, MD EMBA
Absolutely agree! Inclusive clinical trials are essential for developing healthcare solutions that truly benefit everyone. Ensuring diversity in clinical trial designs helps us address the unique needs of various patient populations. #ClinicalTrials #Diversity
If you want the best, then look no further, you found it here.
5dThere is no doubt that it is true that we need to have diversity of race, gender, and age in clinical trials. The concept is not an issue at all. Solving it is more difficult. For myself as an investigator, I am very willing to see anyone who is interested and in need. The biggest issues are primarily socioeconomic. First of all, fundamental education on the importance of studies especially for indigent groups is a major problem as is the cost of manpower at study sites. Who will resolve these issues and how will they get it done? Are sponsors going to provide on-demand transportation to study centers and back home and absorb that cost? In our area we do not have much difficulty related to gender, and due to the large number of Hispanics in our community, we do well in this category. We do have some Black patients, but geographically and logistically, often due to transportation access, this is more difficult for some. Anyone can come to our center and if they meet the protocol criteria and consent to the study, we enroll them.